fda category 2 bulk drug substances bpc-157 just got voted in favor to be added to the 503A list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank FDA to Consider Lifting Restrictions

Mitochondrial-targeted protective potential of elamipretide for the in vitro production of porcine embryos

Another essential component concerns pharmacokinetics (PK) and pharmacodynamics (PD)

Heres who may benefit most once it becomes available: Individuals With Obesity or Insulin Resistance Retatrutide has shown unmatched weight loss efficacy (up to 24.2%) Dramatically improves HbA1c, fasting insulin, and liver fat , making it ideal for those with metabolic syndrome, prediabetes, or NAFLD May reverse insulin resistance and restore metabolic flexibility Athletes in Post-Bulk or Cutting Phases Retatrutides glucagon activity promotes lipolysis and energy burn , making it ideal for fat loss without stimulant use Preserves lean body mass better than other GLP-1s critical during extended calorie deficits Could be stacked with BPC-157, DHEA, or Krill Oil to support recovery and inflammation control Users Who Plateaued on Semaglutide or Tirzepatide For those who saw diminished returns or excessive nausea on other GLP-1s, Retatrutide may offer a more tolerable and effective option , thanks to its balanced GIP and glucagon profile It could serve as a next step for those needing more aggressive results without additional risk Potential Use in Hormonal Recovery Protocols Post-cycle users dealing with fat rebound, insulin resistance, or suppressed metabolism may benefit from Retatrutides ability to increase calorie burn and stabilize blood glucose Could be paired with ZMT and Clean Carbs for comprehensive hormone, sleep, and energy support Important note: None of these uses are currently approved

the largest included sixteen patients and was published in a little-known journal.) On his way out, Lee handed me a copy of a book hed written